Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

NCT04425681 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Leptomeningeal Metastasis
Non-small Cell Lung Cancer
EGFR Activating Mutation

Interventions

DRUG: Osimertinib
DRUG: Bevacizumab

Sponsor

Second Affiliated Hospital of Nanchang University

Collaborators

[object Object]